We also found two potential new cetuximab resistance predictive markers: ANK3 and ANKH. The mutation rates of these two genes in the TCGA HNSCC database were only 3.50% and 1.50%, and the frequency of copy number variations was less than 4.00%. This evidence concerns the gene ANKH and head and neck squamous cell carcinoma.